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Despite decades of laboratory, epidemiological and clinical research, breast cancer incidence 
continues to rise. Breast cancer remains the leading cancer –related cause of disease burden for                               
women,  affecting 1 in 20 globally and as many as  1 in 8 in high income countries 
1
 reducing breast 
cancer incidence will likely require both a population-based approach of reducing exposure to 
modifiable risk factors, and a precision-prevention approach of identifying women at increased risk 
and targeting them for specific interventions, such as risk-reducing medication. We already have the 
capacity to estimate an individual woman’s breast cancer risk using validated risk assessment models, 
and the accuracy of these is likely to continue to improve over time, particularly with inclusion of 
newer risk factors, such as polygenic risk and mammographic density. Evidence-based risk-reducing 
medications are cheap, widely available and recommended by professional health bodies however, 
widespread implementation of these has proven challenging. The barriers to uptake of, and adherence 
to, current medications will need to be considered as we deepen our understanding of breast cancer 
initiation and begin developing and testing novel preventatives.  
 
Introduction  
In high income countries, breast cancer (BC) mortality is decreasing, largely owing to improved 
treatments
2
. Conversely, incidence has been steadily increasing 
3-8
 due in part to an increase in 
diagnosis as a result of the implementation of mammographic screening, but also perhaps implying a 
failure of existing BC prevention strategies
2
. BC  will affect as many as  1 in 8 in high income 
countries by age 85 and remains the leading cancer –related cause of disease burden for 
1
. Prevention 
potentially offers the most cost-effective strategy for cancer control and would reduce the social 
impact of BC. 
Clinically, specific subtypes of BC are defined by their histopathological appearance and expression 
of hormone receptors and growth factors (namely the estrogen receptor (ER), the progesterone 
receptor (PR) and human epidermal growth factor receptor 2 (HER2, also known as ERBB2)). Yet, it 





Both genetic and non-genetic risk factors influence BC development. Genetic factors include 
pathogenic mutations in high and moderate risk cancer predisposition genes (e.g. BRCA1 or BRCA2 
and checkpoint kinase 2 (CHEK2) respectively) and BC-associated common single nucleotide 
polymorphisms (SNPs)
10
. Non-genetic risk factors include increasing age, personal history of breast 
pathologies such as atypical hyperplasia and lobular carcinoma in situ), high mammographic density 
(MD), exposure to therapeutic chest radiation (e.g. for treatment of Hodgkins disease), high body 
mass index (BMI), exogenous female hormone use (e.g. menopausal hormone therapy (MHT) and 
hormonal contraceptives), alcohol, inadequate physical activity, and reproductive factors (early 
menarche, low parity, shorter breastfeeding periods and late menopause). The population frequency of 
some of these genetic and non-genetic factors, and their associations with BC risk are shown in Figure 
1. The distinction between genetic and non-genetic risk factors is not absolute, as many of the ‘non-




This review discusses the evidence for the role of risk factors in driving BC incidence and their 
integration into tools to estimate BC risk for an individual woman - the first essential step towards 
precision prevention. Furthermore, it evaluates existing medications to reduce BC risk and their 
associated challenges, as well as outlines the search to find better alternatives. Lastly, learning from 
the uptake and adherence issues of available medications, it also discusses the priorities that need to 
be considered when developing and implementing alternatives. 
 
Genetic risk factors 
A high incidence of BC in certain families was first noted in 1866
14
; however the most common BC 
susceptibility genes, BRCA1 and BRCA2, were not discovered until the mid 1990s
15,16
. BRCA1 and 
BRCA2 are involved in the repair of DNA double strand breaks through homologous recombination. 
Inherited mutations in these genes account for about 2.5% of all BCs, are responsible for only a 
minority of BCs in women with a strong family history of the disease
17
 and result, on average, in 
about a 70% risk of BC by age 80 years 18. That average high risk is modified up or down for an 





. Other high and moderate penetrance BC predisposition genes include cadherin-1 
(CDH1; which encodes E-cadherin), PTEN, serine/threonine protein kinase 11 (STK11; also known as 
LKB1), TP53, CHEK2, ataxia telangiectasia mutated (ATM), nibrin (NBN) and partner and localizer of 
BRCA2 (PALB2), but germline mutations in all of these are rare
19
. However, they are still included on 
many genetic risk gene testing panels, and additional screening, preventive options and genetic 




Other much more common low penetrance SNPs also affect BC risk. While they confer small 
risks individually, their combined effect, when summarised as a polygenic risk score (PRS), can be 
substantial
21-23
. SNP-based PRS can also be combined with other risk factors in risk prediction models 
such as breast and ovarian analysis of disease incidence and carrier estimation algorithm 
(BOADICEA) and IBIS, which incorporate family history, age, genetic and other risk factors
24
. A 
SNP-based PRS also improves risk prediction in women with pathogenic mutations in rare high and 
moderate penetrance genes
25,26
. Despite the PRS not being routinely used in clinics, there are large 
cohorts currently being assessed to see how SNP-based PRS might affect BC risk management in 
various settings including the WISDOM (Women Informed to Screen Depending On Measures of 
risk) study
27-29
. Additionally, studies to assess chromatin organization are ongoing to identify the 
actual genes affected by the BC-associated SNPs, which are often not located (in the nucleotide 




Non-genetic risk factors 
Whilst obesity and alcohol use both contribute, the increased incidence of ER positive BC is driven to 




Age of menarche and menopause 
Since the mid-19th century the average menarcheal age has decreased from 17 to 12 years of 
age
32,36,37
. The relative risk (RR) of BC increases by 5% for each year younger a women is at 
menarche
38
. Factors known to affect age at menarche include gestational exposure to cigarette smoke, 
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diet, psychological state, maternal weight gain and BMI
39-45
. Moreover, the inverse association 
between BMI and menarche timing is particularly strong
34
. In one sequencing study, 30 new genetic 
loci encoding proteins involved in lipid metabolism and cell growth were shown to be associated with 
menarche timing 46. Additionally, separate studies have shown that increased gestational weight gain 
is associated with a greater chance of obesity in adolescent offspring and excessive maternal weight 
gain has been shown to lower the age at menarche in daughters 34,47,48.  
 
Older age at menopause is associated with an increased RR of BC of 2.9% per year of delay when 
compared to the mean age of natural menopause
32,38,49-51
. The average age of menopause has increased 
from approximately 49 in 1908
52
 to 51.4 now 
53,54
. This 2 year increase in age at menopause would 
instil a moderate 6% increased RR of BC. Menopause timing is affected by socioeconomic status, 
parity, use of the oral contraceptive pill (OCP) and smoking
55
. In addition, through mother–daughter 
and twin studies, it has been demonstrated that 44–63% of the timing can be accounted for by 
heritability 
34
. Polymorphisms within the ER signaling pathway have also been found, but more work 
is required to determine what this means for the level of ER signaling 56,57. Further implicating 
hormones in menopause timing, women with a later menopause have longer menstrual cycles and the 
latter is suggested to be related to hormone levels in the follicular phase 58. Research in pre-clinical 
models and women where possible should focus on determining why the breast is particularly 
sensitive to cancer risk if there are changes in hormonal exposure at both the beginning and end of 
reproductive cycling 34. 
 
Childbearing 
Women are having fewer children (and often later in life) which also increases BC risk, an association 
identified in the 18
th
 century when nuns were found to have an increased risk of BC
59
. Childbearing 
prior to 35 years of age provides longer term protection against BC with the age of first birth being 
particularly important. If aged < 20 years, the longer term RR is reduced by 70% compared with 
nulliparous women. As the age at first full term birth increases, the longer-term protection from parity 
is progressively lost
35
 and for those women who begin childbearing after age 35, the risk of BC is 
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higher than for nulliparous women
35,60
. This parity associated protection has been shown to be 
specific for ER positive BC
61-63




In Australia, as in other high income countries
66-68
, fertility rates have dropped to an average of 1.7 
children per woman (compared to 3.5 in 1960 and 5 earlier in the 20
th
 century), almost a quarter of 
women will remain nulliparous
69,70
 and over 60% of parous women delay childbearing until after age 
30, which provides little or no BC protection
71
. Older age at first birth is most common among highly 
educated women
69
 (average age of first birth in the USA in 2017 was 3.5 years older for college-
educated women
72





The protection afforded by pregnancy is not immediate; first there is a period of increased risk as the 
breast undergoes a post-partum involution process to return to its pre-pregnant state. This takes on 
average 10 years 75. Older age of first-time childbearing means that this transient increased RR of BC 
after birth is more important because baseline BC risk increases with age and also the transient 




The mechanisms that underlie the protection from BC following childbirth have not been defined. A 
reduction in the number of mammary stem cells (MaSCs)
76
 and reduced sensitivity to estrogens
77
 have 
been postulated. MaSCs are thought to be the cells of origin for carcinogenic transformation
78,79
, and 
therefore, reduced levels of them would leave the breast less susceptible to tumorigenesis
80
. In support 
of this, the RR of BC owing to radiation exposure is highest in young women, whom, it is proposed, 
acquire radiation-induced mutations (environmental exposure or for treatment of other cancer types) 
in long lived MaSCs
81,82
. Moreover, rat mammary glands are most sensitive to dimethybenz-(a)-
anthracene (DMBA) induced carcinogenesis in puberty, when terminal end buds (believed to serve as 
niches for MaSCs) are most abundant
79
. However, mouse studies directly assessing the role of MaSCs 
in parity protection have provided conflicting results 
83-85
 with one study in particular showing that 





Our group has recently provided some insight into this controversy by demonstrating that whilst 
cellular repopulating activity is reduced by parity, it is not due to the classically defined MaSCs (Britt 
and colleagues unpublished data). Additionally we have also shown that the number of ER positive 
epithelial cells are decreased by parity leaving the breast less sensitive to the pro-proliferative effects 
of estrogen
77
. In line with this, Jindal and colleagues have also shown that breast tissue of parous 




The immune microenvironment may also contribute to parity induced protection. However, the 
relationship is complicated by the fact that protection occurs only after women pass through an 
increased risk period immediately following the pregnancy as the breast undergoes post-partum 
involution. During the involution process (first five years post pregnancy in women, and first weeks 
in mice) there are increased myeloid cells which can dampen the adaptive immune response and lead 
to a pro-tumorigenic environment 
75,88,89
. However, once involution completes parous women are 
afforded long-term protection against BC. The immune changes that occur in the resting parous 
women are long-term changes to the breast and may mediate the decreased BC risk in parous women.  
Resting parous breast has an enrichment of genes involved in immune-surveillance (SARM1, T cell 
receptor β (TCR), human leukocyte antigen-A24 (HLA-A24) and interleukin-22 receptor subunit α2 
(IL22RA2)) when compared to nulliparous postmenopausal glands 
89,90
.  These genes are instrumental 
in triggering innate immune responses, activating T cells, eliciting cytotoxic T cell anti-tumor 
immunity, and promoting apoptosis of tumor cells.  Further work is needed to align these gene 
expression changes to the specific protective changes in the immune microenvironment.  
Understanding these may allow us to begin assessing the potential of therapeutically instilling a 
protective immune microenvironment.  
 
Breastfeeding 
For every 12 months of breastfeeding, there is a RR reduction for BC of ~4%
31,73,91,92
. Importantly, the 
protection conferred by breastfeeding is not limited to ER positive BC 
61,93,94
. The mechanisms of 
breastfeeding-induced protection are largely unknown; however, glycoproteins stanniocalcin-1 
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(STC1) and STC2 are increased during lactation and these in turn inhibit protease pappalysin-1 (also 
known as PAPP-A), an oncogene that is increased during pregnancy, which along with insulin-like 




Current breastfeeding rates are much lower than the recommendation of the World Health 
Organization (WHO), which calls for breastfeeding only for the first 6 months of life, with continued 
breastfeeding and complementary foods up until two years of age or beyond
96
. In Australia and the 
UK respectively, 90% and 69% of women initiate exclusive breastfeeding; however 50% and 23% of 
these have ceased by 6-8 weeks
97-99
. Moreover, Victora and colleagues
100
 found that in low-income 
and middle-income countries, only 37% of children younger than 6 months of age were exclusively 
breastfed. Breastfeeding rates and duration could potentially be rapidly increased by scaling up known 
interventions, policies and programs, such as lactation support programs, reinforcing a breastfeeding 
culture (e.g. by removing actual and perceived restrictions on breastfeeding in public), adequate paid 
parental leave, flexible working arrangements and prohibition of aggressive and inappropriate 





MD is the extent of white or radio-opaque tissue (dense area) on a mammogram, and the term percent 
MD (PMD) is used to represent this dense area as a proportion of the total tissue area of the breast on 
a mammogram. There are multiple ways to measure MD and controversy exists over the measure that 
best correlates with BC risk. The Breast Imaging Reporting and Data System (BI-RADS) is the most 
commonly used tool clinically and includes 4 categories (almost entirely fat, scattered density, 
heterogeneously dense, and extremely dense)
102
. Limitations of the BI-RAD assessment include that it 
provides crude categorical estimates of density (rather than a continuous measure) and is reader 
dependent. There have been 5 BI-RAD editions with the 2017 release including clarification of 






Many studies have demonstrated that, after adjustment for age and BMI, MD is an independent risk 
factor for BC, with a RR ranging from 1.8 to 6.0 in women with high MD (HMD) when compared to 
those with low MD (LMD)
104
. A systematic review and meta-analysis of 42 studies found that the 
RRs for BC were 2.92 and 4.64 for women with heterogeneously dense or extremely dense breasts 
respectively, compared to women with almost entirely fatty breasts
104
. Hopper and colleagues showed 
that measures of MD may explain more variation in risk across the population than known genetic 




HMD is an important BC risk factor, not only because of the magnitude of the risk with which it is 
associated, but because it is highly prevalent; 43% of women in high income countries aged 40-74 
have extremely or heterogeneously dense breasts
107
. In the United States (US), this corresponds to 
more than 27.6 million women. The US and the state of Western Australia are the only places where 
standardized mammographic reporting includes a MD measure, largely resulting from consumer 
advocacy campaigns. The lack of routine MD reporting globally may be owing to controversy over 
which density measure best correlates with risk and a lack of clear clinical pathways for management 
of women with HMD.  
 
Although generally considered a non-genetic risk factor, twin studies have demonstrated that about 
60% of the variation in MD is explained by genetic factors
13
. The pathobiology underlying HMD is 
not well understood but recently has been correlated with increased levels of stroma and epithelium
108
 
as well as immune cells
109
 compared with LMD (Figure 2). 
Lastly, MD is also emerging as a potential biomarker for prevention. A reduction of MD greater than 
10% following treatment with a selective ER modulator (SERM), tamoxifen has been associated with 
a 63% BC risk reduction (odds ratio (OR): 0.37) 110. However, the case for aromatase inhibitors 
(which reduce post-menopausal estrogen synthesis) is not as strong 111. The reasons why MD is 
appealing as a predictive biomarker are that it is strongly associated with endocrine exposure, is non-
invasively measured and can be incorporated into routine patient management. Nevertheless before it 
is introduced we need to determine the change threshold in MD that best predicts improved outcome, 
10 
 
the most accurate predictive parameter of MD i.e. percent density vs. absolute measures or categorical 
density (BI-RAD, Boyd or Wolfe) 
112,113
 and how we should interpret MD i.e. visual vs. computer 
assisted vs. fully automated methods.  
 
Overweight and obesity 
High BMI in the post-menopausal years is associated with a significant increase in BC risk, although 
it appears protective in premenopausal women. Specifically, in an international meta-analysis of 10 
studies from 9 prospective cohorts and 22 case control studies, postmenopausal women in the highest 
body weight categories had an 82% increased RR for ER positive BC compared with those in the 
lowest body weight categories; there was no association with the other BC subtypes
114
. Conversely, 
pre-menopausal women in the highest body weight category had a 20% lower risk of developing ER 
positive BCs (similarly, there was no association with the other BC subtypes). Several mechanisms 
have been proposed to explain the link between increased BMI and cancer risk including increased 
conversion of androgens to estrogens, insulin and insulin-like growth factor (IGF) signalling, 
adipokine pathophysiology and chronic inflammation
115
. For BC specifically, the case for hormonal 
stimulation is supported by in vitro and in vivo experimental data 
116
 and the fact that male BC risk 





The Iowa Women’s Health and Nurses’ Health studies showed that women who maintained or lost 
weight as they got older had a reduced RR of post-menopausal BC 
118,119
 . This is supported by earlier 
epidemiological studies showing >10kg weight loss between 22-44 years of age was associated with 
an OR of 0.6
120
. Meta-analyses have also confirmed adult weight gain is associated with increased 
post-menopausal, but not pre-menopausal BC risk 
121
. However, it is only those women with BMI of 
<23.4 kg/m
2 
at age 20 years who had their BC risk influenced by adult weight gain 
122
. It is not clear 
why the BMI at age 20 impacts postmenopausal BC risk, but it is postulated to be due to hormonal 
differences in adolescent girls with high BMI 
122





Independent of BMI - mediated risk reduction, moderate to vigorous physical activity is associated 
with about a 20% reduced RR of BC when comparing the most to least physically active women 
123-
126
. Informed by these findings, the World Cancer Research Fund has concluded that physical activity 
probably protects against BC 127. Independent of changes in adiposity, mechanisms that may account 
for this protection include physical activity effects on estrogen metabolism, insulin sensitivity, chronic 
low-level inflammation, oxidative stress, and immune function
124,126
. Physical activity-induced 
transcriptional changes are also possible
128,129
. Experimental studies have also directly addressed why 
exercise is beneficial. For example, the colony forming ability of non-small-cell lung cancer 
(NSCLC) cells is reduced by 80% after pre-incubation with conditioned serum from exercised 
individuals
130
 and tumour incidence in mice is halved
131,132
. Work is underway to define the molecular 
signals underlying this. Whilst the optimal level of physical activity necessary for BC prevention is 
not clear with more than half the population in high income countries (including Australia, UK and 
the US) not meeting the recommended physical activity guidelines
133




Data from the Nurses’ Health Study showed that women consuming 5-10 grams of alcohol per day 
(i.e. 3-6 glasses of wine per week) were 15% more likely (RR 1.15) to develop BC than non-drinkers, 
and those consuming at least 30 grams per day (i.e. at least 2 drinks per day) were 50% (RR 1.50) 
more likely
134
. Similar results were found in the Million Women Study
135
. A large prospective pooled 
Australian cohort, Arriaga et al., 2019
136
 have recently shown that regular alcohol consumption is the 
leading modifiable cause of BC burden for premenopausal women, explaining 12.6% of BCs.  
 
The mechanism by which alcohol (now considered a class I carcinogen by the international agency 
for research on cancer (IARC)) increases BC risk is an active area of study. Ethanol is known to 
stimulate cell proliferation and the transcriptional activity of ligand activated ER, which in turn 
increases levels of circulating estrogen levels
137,138
. Ethanol metabolism takes place mainly in the liver 
12 
 
where it is oxidized to acetaldehyde by the alcohol dehydrogenase (ADH) enzymes; however, ADH 
enzymes are also expressed in the breast 139. Acetaldehyde can induce DNA strand deletions, 
chromosome aberrations and DNA adducts and is considered mutagenic and carcinogenic
140
. 
Furthermore, some experimental work has been performed in mice looking at the effects of alcohol on 
the immune response to cancer 
141
. They found that CD8 cytotoxic T cells (which are capable of 
killing tumour cells) were decreased, in particular the CD8 memory T cells, which allow an efficient 
anti-tumour response should re-infection occur.  Myeloid derived suppressor cells were also 
increased, which supress T cell responses and an increase in CD3+ invariant NKT cells that had a pro-
tumorigenic expression profile
141
. Overall this suggests that alcohol supresses the ability to the 
immune system to respond to cancer.   
 
The World Cancer Research Fund  and the American Institute for Cancer Research (AICR) report 
recommends that if alcoholic drinks are to be consumed, that this is limited to no more than two 
drinks a day for men and one drink a day for women
142
.  Although earlier research supported potential 
health benefits for low to moderate alcohol intake
143
, more recent, methodologically robust research 
has concluded that the safest level of alcohol intake is none
144
. Alcohol is an ingrained aspect of the 
culture in many parts of the world. Reducing population intake of alcohol will require government 
commitments to developing and implementing policies similar to those that have reduced smoking 
rates in many jurisdictions, such as increased alcohol taxation, control of the physical availability of 
alcohol and hours of sale and banning alcohol advertising and implementing plain packaging.  
  
Lifestyle  
It is important to note that the benefits of a healthy lifestyle in terms of reducing BC risk are 
particularly important, in absolute terms, in women at high familial risk of the disease. We have 
shown that the RR for associations between BC risk factors such as BMI and physical activity are 
similar regardless of the underlying familial risk; this means that the absolute risk associated with 
higher BMI or lower physical activity is much greater for women at high familial risk compared with 
those at population risk 
145,146
. Therefore, it is crucial that the larger potential benefits for lifestyle 
13 
 
changes are explained to women at increased risk who may otherwise feel that the familial factors are 
so overwhelming that there is little to be gained by lifestyle adjustment. Unfortunately, there is very 
limited interventional trial data on lifestyle changes. However, one study, the women’s health 
initiative (WHI) dietary modification trial, showed that reduced fat intake and increased consumption 
of vegetables, fruits and grains led to a 5% reduction in BC risk (Hazards ratio (HR): 0.95) at the 
long-term follow-up (19.6 years) 
147
. Further well designed lifestyle intervention trials assessing 
impacts on BC risk are needed and will surely help to convince those at risk of the impact these 
changes could have on their personal risk. 
 
BC risk in diverse populations   
The National Cancer Institute (NCI)'s Surveillance, Epidemiology, and End Results (SEER) program 
showed that in the U.S. the age-adjusted BC incidence for ethnic minorities was lower than those for 
white women, with 141 cases per 100 000 in white women, 122 in African Americans, 97 in Asian 
and Pacific Islanders, 90 in Hispanics, and 58 in American Indians and Alaskan Natives 
148
. The 
difference in risk factors across the ethnicities and the use of screening mammography could explain 
some of the differences, but BC incidence was still significantly lower in African Americans than 
whites when adjusted for these differences
148
. Despite the lower overall incidence, African American 
women are more likely to be diagnosed with advanced and largely ER negative BC compared with 
white women 
149
. Whilst the reason for these differences is not fully understood, it may involve the 
known associations between certain risk factors and disease subtypes. For example, multiparity and 
early first pregnancy protect against ER+ luminal BC, but do not protect against the development of 




Heritability analyses show that BC is a highly polygenic disease 
151
. In addition to the rare, high risk 
alleles, there are common variants with a small effect on risk (Figure 1). The use of a PRS assessing 
the effects of these variants on risk has only been thoroughly validated in European populations. Only 
the Breast Cancer Risk Assessment Tool (BCRAT) from the national institutes of health (NIH) has 
been validated for use in black or African American women, Hispanic women and Asian and Pacific 
14 
 
Islander women  
152-154
.  Genome wide association studies (GWAS) in multiple ethnicities such as the 
National Cancer Institute led Confluence project (300,000 BC cases and 300,000 controls) will drive a 




[H1] Predicting BC risk  
A key component of optimal precision prevention is the capacity to accurately estimate a woman’s 
BC risk. This facilitates the use of evidence-based prevention interventions appropriate to the 
woman’s personal risk level. It also enables calculation of the absolute risk-reduction from preventive 
interventions, thus assisting informed decision making.   
 
BC risk estimation models now exist which attempt to quantify the combined effect of many of the 
BC risk factors discussed above
155
. Many of these have not undergone independent validation in study 
populations other than those used in their development and will not be considered further here. The 
independently validated models vary regarding the risk factors they utilise. The risk factor inputs for 




Of the validated models, most
156,157,159,166,170-174
, but not all
160,167-169,175
, incorporate non-familial risk 
factors to varying degrees. The IBIS model encompasses the most comprehensive list of risk factors 
and performs well in comparative validation studies
158,176-179
. Polygenic risk to SNPs has been shown 
to predict BC risk almost independently of other factors, including MD
179
, and the IBIS model is the 




The performance of risk prediction models is often measured based on their discriminatory accuracy 
and calibration. The performance of the various BC risk prediction models varies, with discriminatory 
accuracy ranging from 0.56 to 0.71 (poor to good)
181
 and calibration ranging from 0.85 to 1.52 
according to a recent systematic review
182
. Work is ongoing to improve the accuracy of these risk 
15 
 
prediction models. For example,  common risk prediction models do not currently include  some 
modifiable risk factors such as  alcohol, hormonal contraception use, physical activity or time since 
last pregnancy. It will also be important to determine if additional, more novel risk factors, such as 




 and double-strand 
DNA repair phenotype
185
, will give maximal improvement to the models. Incorporation of new risk 
factors into existing models will require consideration of potential interactions with existing risk 
factors and extensive validation, preferably using prospective data.  
 
The current models have other limitations besides their limited discriminatory accuracy. Firstly, the 
models tend to have different performance characteristics depending on the subset of women they are 
applied to, but many clinicians are not skilled in choosing the most appropriate risk model, nor do 
clear guidelines exist
186
. A related issue is that the models have been developed and validated largely 
in populations of European descent, so their accuracy in estimating BC risk for women of other 
ethnicities is uncertain. Importantly, none of the major validated risk estimation models couple the 
risk estimation to comprehensive, personalised BC prevention and screening advice, nor estimation of 
the absolute risk reduction that can be achieved. And lastly, most have user interfaces that are difficult 
for women and less experienced clinicians to use. We have recently developed iPrevent
187
 to 
overcome these issues and to facilitate collaborative decision making about BC risk management, 
between women and their clinicians. Women can complete the tool online at home and print the 
output for discussion with their clinician. It has been independently validated, is well calibrated and 
has good discriminatory accuracy (0.70 overall and 0.74 for women under age 50) 
188
. It has good 
acceptability and usability for both women and clinicians and seems to improve the accuracy of risk 




To date, all of these BC risk models have generally been used on an ad hoc basis and to our 
knowledge, there has been little consideration of population-based risk assessment followed by 
targeted risk reduction, despite the potential of precision prevention to reduce BC incidence. 
16 
 
Targeted risk reduction might include modifying specific risk factors (such as alcohol intake, use of 
MHT and hormonal contraceptives, physical inactivity and obesity) contributing to each woman’s 
personal risk and, for some women at higher risk, consideration of risk-reducing medication. It is 
known that consumers find the constant information about BC risk factors in the media and other 
sources confusing, and are often uncertain how it pertains to them as individuals, with many having 
expressed a preference for more targeted information
190
. In Australia, formally assessing BC risk at 
the time of (free, government-funded) breast screening in order to risk stratify women for different 
screening approaches is currently being considered. However, given that breast screening usually 
starts at age 50, such an approach would provide no opportunity to prevent the approximately 20% of 
BCs that occur before that age 
191
. We suggest that consideration should be given to routine risk 
assessment of women in the general population in early adulthood (and at regular intervals thereafter, 
given that risk factors change over time). Nevertheless it will be important to 1) identify a risk 
assessment tool that is accurate and easy to use, 2) show that such risk assessment results in 
behavioural change and uptake of risk-reducing medication that will reduce BC risk without 
increasing anxiety beyond acceptable thresholds, and 3) determine the cost, suitability and feasibility 
of such an approach in different healthcare systems and among different subgroups (e.g. by ethnicity, 
age and socioeconomic status).  
 
Currently Available Preventive Options  
Women at increased risk of BC have several options to reduce their risk, including surgery, 
medication and lifestyle options (the last is also relevant to women at moderate risk). Table 2 




Risk-Reducing Bilateral Mastectomy  
The most effective measure for reducing BC risk is bilateral mastectomy, although guidelines 
recommend limiting this to women at substantially increased risk. There are no randomised trials of 
this intervention, but observational studies show it is associated with a 90% reduction in risk
195,196
. 
Immediate breast reconstruction is usually offered, although it is associated with much higher rates of 
17 
 
unanticipated reoperations. Most women are satisfied with their decision to have bilateral risk-
reducing mastectomy and have a significant reduction in worry-associated with getting BC, but there 
is less satisfaction with cosmetic results, body image, and sexual feelings
197
.  Risk-reducing 
mastectomy that spares the nipple has better cosmetic outcomes than simple or skin-sparing 
mastectomy, and limited data suggests it confers similar risk reduction
198
. Uptake of risk-reducing 
bilateral mastectomy in high risk women is highly variable, with high uptake rates in the US, UK, 




Bilateral Salpingo-oophorectomy  
Bilateral salpingo-oophorectomy is effective at reducing the risk of cancers of the ovary and fallopian 
tube. BRCA1 and BRCA2 mutation carriers are generally counselled to consider this procedure by the 
age at which their ovarian and fallopian tube cancer risk increases above that of the general 
population, that is by late 30s (for BRCA1 carriers) and late 40s (for BRCA2 carriers)
18
. Historically 
these women have also been counselled to consider the procedure at an earlier age (after childbearing) 
in order to reduce BC risk. Randomised trial data on the efficacy of bilateral salpingo-oophorectomy 
in reducing BC risk are not available. Earlier studies suggested a halving of BC risk for mutation 
carriers who underwent risk-reducing salpingo-oophorectomy (RRSO)
200
; however issues related to 
the methodology used in this study have been raised
201
. Furthermore, recent prospective cohort studies 






Modification of non-genetic risk factors, such as obesity, alcohol use and lack of physical activity is 
an important component of BC prevention. In general, these non-genetic risk factors confer similar 
RRs of BC in high risk women as for those in the general population
205
. Unfortunately, lifestyle 
modification can be difficult to achieve and sustain. Therefore, focus on the development of 
efficacious interventions for behavioural change as well as government policies, as already discussed, 
to support healthy lifestyles will be essential.  
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Clinically Available Risk Reducing Medication 
Risk reducing medication is an important prevention option for women at increased risk of BC who 
do not wish to undergo (or who wish to postpone) risk-reducing mastectomy or whose risk is 
increased but not elevated enough for surgery to be considered appropriate. The risk-reducing 
medications recommended in international guidelines are the selective ER modulators (SERMs), 
tamoxifen and raloxifene, and the aromatase inhibitors, exemestane and anastrozole (see Table 2). 
None of these have been shown to reduce BC mortality and all of them are only able to reduce risk of 
ER positive BC. Nevertheless, ER positive BC is the most common type and avoiding a BC diagnosis 
and subsequent treatment, even if that BC was not going to result in premature mortality seems a 
worthwhile goal in terms of reducing burden on the healthcare system, women and their families.  
 
Tamoxifen is the best studied risk-reducing medication and is the only preventative agent that has 
been demonstrated to be effective in pre- and post-menopausal women. It reduces ER-positive BC 
risk by 33%
206
, with the risk reduction seen not only during the 5 years whilst taking the medication, 
but also for at least 15 years after cessation
207
. Reductions in MD in tamoxifen users correlate with its 
preventive efficacy
110
. However, side-effects of tamoxifen can include menopausal symptoms, such as 
hot flushes, and a doubling of the risk of thrombosis, although the absolute risk remains low, 
particularly in younger women
208
. Tamoxifen also doubles the risk of endometrial cancer in post-
menopausal women, although again the absolute risk is small
208
. Another major impediment to uptake 
of tamoxifen by pre-menopausal women for a 5 year period is the inability to prescribe it safely in 
women who are trying to conceive, who are pregnant or who are lactating and the fact that women 




Another SERM, raloxifene has only undergone trials in postmenopausal women. Raloxifene (60mg 
daily for 5 years) was compared directly with tamoxifen (20mg daily for 5 years) in the STAR trial 
and at the 81 month median follow-up raloxifene was only 76% as effective at reducing ER-positive 
BCs compared with tamoxifen, but without the increased endometrial cancer risk seen with tamoxifen 
and with fewer thromboembolic events
210
. Risks and benefits of treatment with raloxifene or 
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tamoxifen in post-menopausal women depend on age, ethnicity, BC risk, and hysterectomy status. 
Tables have been published for both tamoxifen and raloxifene that can help identify groups of women 




Randomised controlled trials of the aromatase inhibitors exemestane and anastrozole have also shown 
that these medications can reduce BC risk by 60% at median 2.5 years follow-up and 49% at median 
10.9 years follow-up, respectively
212-214
. These medications can only be used in post-menopausal 
women as they are ineffective in women with functioning ovaries.  
 
Despite the clear benefits of risk-reducing medication, uptake is low among women at increased 
risk
215,216
. The reasons are complex and both clinician and patient-related. There is lack of clarity over 
the most appropriate type of clinician to initiate discussions about risk reducing medications
186,215
, in 
addition to clinicians having difficulty using the existing risk assessment models
215,217
, and preferring 
to have a tool that links risk assessment with risk management 
217
. Furthermore, clinicians often lack 
deep knowledge about prevention medications
218-220
 and are concerned over the lack of surrogate 
markers for the effectiveness of preventive medications as well as the overall lack of commercial 
interest in prevention
215
. The latter concern comes about because all current prevention medications 
were off-patent by the time their role in prevention was proven. Thus, unlike newer patented drugs, 
where companies have a commercial incentive and spend considerable proportions of their budget 
educating clinicians about their drug, there is no investment to educate clinicians about implementing 
these older generic prevention medicines into their practice. Additionally, in some countries/regions 
in Europe and in Australia, there is lack of a clear pathway for regulatory approval of repurposed, off-
patent drugs. Tamoxifen was shown to reduce BC risk in 1998 221, and was promptly approved by the 
US food and drug administration (FDA) for primary prevention but in Australia regulatory approval 
was not sought until 2016 and only then after substantial advocacy by clinicians and consumer 







The major patient factor contributing to low uptake of risk-reducing medications is said to be fear of 
side-effects
222,223
. However, in the main prevention trials, fewer than 5% of women ceased treatment 
because of side-effects 
213,214,221,224
. Clinician recommendation and the way clinicians frame 
information about side-effects is important. For example, regarding the risk for endometrial cancer for 
post-menopausal women, it may be better to frame the risk as “approximately 996 in every thousand 
women can take tamoxifen for 5 years without getting endometrial cancer”, rather than “your risk is 
doubled”. Few online tools are available currently to help clinicians balance absolute benefits against 
absolute risks for individual women
187
. Clinicians should also be sure to convey not only potentially 
adverse side-effects, but also beneficial ones, such as, for example, the potential for decreased breast 
tenderness, lighter menstrual periods, better bone density and lower cholesterol for women 
considering tamoxifen use. Clinicians should also consider offering women a short trial of 6-8 weeks 
of risk-reducing medication to assess their tolerance and so that women do not feel they are 
committing to a 5 year course with no knowledge of how well they, as an individual, will tolerate the 
drug. If such a short trial also had a biomarker of effectiveness, it may assist women in drug 
adherence.  
 
Other patient factors that limit uptake of tamoxifen for ER-positive BC risk-reduction include the fact 
that it is a cancer drug, the experience of others (usually those with cancer), and the tablet being a 
daily reminder of their increased cancer risk; although the latter can presumably also work in reverse, 
with some women reassured by the daily tablet that they are actively reducing their BC risk
222
. 
Importantly it has also been shown that women often confuse tamoxifen with chemotherapy, and this 
has led to recommendations that the word ‘chemoprevention’ should be avoided
222,225
 with ‘risk-
reducing medication’ seemingly a more appropriate term.  
 
 Developing novel preventive agents  
The ‘perfect’ risk-reducing medication would be highly efficacious, have minimal adverse side effects 
but potentially several beneficial ones, and be able to be used even if on hormonal contraception or 
during pregnancy or when lactating. It could potentially be a long-acting depot preparation, avoiding 
21 
 
the need for a daily tablet, and would not be associated in the public mind with a cancer drug. It 
would be inexpensive and preferably developed in a way that facilitated rapid regulatory approval and 
engagement of the pharmaceutical industry in implementation. Ongoing trials of BC prevention 
medications are summarised in Table 3.  
 
One tactic to provide a new approach to risk-reducing medication that has fewer adverse side-effects 
than current agents is to modify the dose and delivery system of available agents. Tamoxifen is 
largely a pro-drug that is metabolised to its active metabolites, including endoxifen, by hepatic 
enzymes (e.g. cytochrome P450 2D6 (CYP2D6)) 226. Biomarker studies have suggested that 5mg per 
day is equivalent to the usual 20mg per day dose in inhibiting BC proliferation
227
, suggesting that low 
dose tamoxifen might be efficacious for prevention. Furthermore, a recent multicentre, randomised 
trial suggested that a lower dose and duration of tamoxifen (5mg daily for 3 years) might have similar 
BC prevention efficacy as the usual 20mg daily for 5 years dose, with fewer side-effects. 
Unfortunately, these 2 tamoxifen regimens were not compared against one another but, based on this 
trial
228
, 5mg of daily tamoxifen for 3 years is now a reasonable BC prevention option for women who 
do not tolerate dosing at 20mg. It will be important to assess whether this smaller dose for a shorter 
duration provides the same long-term risk-reduction as 20mg daily for 5 years and whether CYP2D6 
status affects the efficacy of the smaller dose. Another approach to potentially reduce the side-effects 
of tamoxifen is transdermal therapy which can result in high drug concentrations in the breast, but low 
systemic exposure. A window of opportunity trial in patients with ER positive ductal carcinoma in 
situ (DCIS) (NCT00952731)
229
 showed oral and transdermal delivery both decreased (by 50-60%) 
expression of the proliferation marker Ki67. Atossa Genetics recently announced the results of a 
phase II study of daily topical endoxifen applied to the breasts, which showed reductions in MD in 
women using the transdermal medication, with no difference in menopausal side-effects between the 
topical endoxifen and placebo groups, although the duration of treatment was limited by skin rash.  
Metformin is a drug that is commonly used to treat type 2 diabetes 230. Metformin users have a 
decreased incidence of cancer, and more long-term use (≥ 5 years) is associated with a reduced, 
adjusted OR of 0.63 for developing BC 231. This, and promising pre-clinical work has led to the phase 
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III randomized control trial (the PLOTINA study EudraCT Number 2009-009921-28) 232, comparing 
metformin versus placebo in post-menopausal women at high risk of type 2 diabetes.  
 
Bisphosphonates, originally used as a treatment for osteoporosis, have been shown in pre-clinical 
studies to inhibit BC proliferation and metastasis and have been proposed as BC preventives 233-236.  
They are currently used in patients with metastatic BC to reduce skeletal-related events, and their use 
in the adjuvant setting in post-menopausal women reduces mortality
237
 and is recommended in North 
American and European guidelines
238,239
. Women who take bisphosphonates for bone density have 
reduced BC incidence (20-47% lower depending on the study)
234,240
 suggesting a possible role in BC 
prevention. Conversely, they do not reduce contralateral BC risk when given adjuvantly
237
. An 
interventional prevention trial is underway (NCT02781805)
229
 assessing the effects of the 
bisphosphonate, alendronate, on mammary epithelial cell differentiation and immune cells in high risk 
women.  
 
Retinoids are another class of drugs that are currently in BC prevention trials (EudraCT Number 
2009-010260-41 and NCT03323658) 
229,241
. Retinoids are anti-proliferative, cyto-differentiating and 
apoptotic through their activation of the nuclear hormone retinoic acid receptor α (RARα), RARβ and 
RARγ. Strong data in pre-clinical models using the retinoid fenretinide
242
 led to a phase III prevention 
trial in the late 1980s. Fenretinide showed a trend for reducing the incidence of second primary BCs 
in premenopausal women (HR: 0.66 and HR: 0.65 for contralateral and ipsilateral BC respectively), 
which was maintained at 15-year follow-up
243
. This drug has a very low toxicity profile (mainly 
reversible skin dryness and rashes as well as difficulties adapting to darkness) which are often 
overcome by a monthly weekend suspension of the drug. However, it is not safe for pregnant women 
and so has similar reproductive contraindications in pre-menopausal women as tamoxifen. Yet, the 
results of these novel BC preventative trials are eagerly awaited.  
 
Medical prevention of BCs in BRCA1 mutation carriers has been controversial. These women usually 
develop ER negative BC, and existing prevention agents have not reduced ER negative BC in clinical 
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trials, although observational data in the secondary prevention setting
244,245
 show that tamoxifen is 
associated with reduced contralateral BC risk. There is growing evidence suggesting that receptor 
activator of nuclear factor-κB (RANK; also known as TNFRSF11A) and its ligand (RANKL) play a 
pivotal role in the development of BRCA1mutant-associated tumors. RANK
+
 luminal progenitors are 
increased in pre-neoplastic tissue of BRCA1 mutation carriers compared with non-mutation carriers
246
. 
Moreover, these cells have been identified as the cell of origin for the basal-like BC that develop in 
BRCA1 mutation carriers. Pre-clinical studies in Brca1-deficient mice targeting these cells with the 
RANKL inhibitor (and osteoporosis drug) denosumab successfully inhibited tumour development
247
. 
Preliminary data from a preclinical window study to evaluate the biological effects of the denosumab 
on breast tissue biopsies from BRCA1 mutation carriers showed proliferation was markedly 
reduced
246
. An international phase III randomised trial of denosumab is testing whether administering 





There is also interest in anti-progestins (synthetic progestogens) for BC prevention. Treatment of 
BRCA1 deficient mice with the progesterone antagonist mifepristone inhibits tumorigenesis
249
. 
Mifepristone is considered too toxic to move into the prevention setting, but other less toxic 
progesterone receptor modulators are under investigation (NCT02408770)
250
. Aspirin, other non-
steroidal anti-inflammatory drugs (NSAIDs), and the statins are inexpensive, widely available and 
relatively safe drugs, making their potential repurposing for BC prevention an attractive strategy. 
Whilst mature, randomised trial data are not available for any of these agents in the BC primary 
prevention setting, at a dose of ≥2 times per week aspirin use for 5 years was associated with reduced 
BC risk (RR: 0.86), with decreasing risk with longer duration (RR: 0.73 for 10 years and RR: 0.54 for 
20 years)
251
. Similar results are observed with another type of NSAID, the cyclooxygenase 2 (COX2) 
inhibitors
252
. Recent work assessing these associations in a cohort enriched in women with a strong 
family history showed regular aspirin was associated with a 37-39% reduction in BC risk, whilst for 
COX2 inhibitors it was 61-71%
253
. Some studies have found that aspirin and COX2 inhibitors reduce 
both ER positive and ER negative BC
253





Large scale, randomised controlled trials with both population risk women and those at higher risk are 
needed to define the true benefits of long-term aspirin use in the preventative setting.  
  
For all of these preventatives, a major task will be determining the best timing of preventative 
therapy. It is possible that preventive therapy may be delivered immediately prior to the age 
dependent increase in risk of hormonal BCs or the likely age of onset for familial cancers. This would 
drive high protection levels during the most crucial time. The 96-month follow-up of the randomized 
IBIS-I trial showed that 5years of taxoxifen prevention provided better protection in late 
premenopausal women (35-50 years old) rather than women 50 years or older (RR: 0.65 vs RR: 0.79) 
257
. Instead, aromatase inhibitors offer an attractive alternative for postmenopausal women. However, 
as the time between puberty and first pregnancy is known to be a window of risk 
34
, ongoing work 
should determine why this period is so important and if it is also the most effective time to deliver 
long-lasting preventative therapy. Prevention trials are, by their very nature, quite lengthy and thus 
clinical trials assessing the impact of new therapies on early breast lesions (such as, hyperplasia and 
in-situ carcinoma) can be informative when assessing efficacy.  
 
A deeper understanding of the earliest steps in BC development will aid in our quest to develop novel 
preventatives. The normal breast epithelium contains numerous cell types and is imbedded within a 
dense stromal and immune microenvironment 258,259.  Epithelial changes occur in BRCA1 mutation 
carriers at risk of BC 
246
 and it is possible that other epithelial cell subtypes may be increased under 
alternate risk conditions (Figure 3).  Additionally, the stromal and immune microenvironments play a 
significant role in the growth and progression of pre-invasive and invasive BC
258,260
 and can stimulate 
tumour development in the normal post-partum breast
88
. The microenvironment of early lesions and 
breasts at risk of cancer should be studied in order to determine whether these cells can be targeted for 
BC prevention (Figure 3). 
  
Conclusions and perspective 
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To date, BC prevention in most parts of the world, has largely focused on untargeted, population-
based educational interventions (such as, increasing physical activity and reducing BMI and alcohol 
intake). This will remain an appropriate component of BC prevention, as these interventions also 
reduce risk of other important causes of morbidity. However, we are moving towards the ability to 
augment this approach with systematic targeting, or precision prevention. Precision BC prevention 
will mean delivering the right risk-reducing intervention, at the right time, to the right woman. A vital 
starting point will be to have a systematic and accurate method of assessing each individual woman’s 
BC risk. Risk assessment models currently exist and their accuracy will continue to improve. 
Developing better risk assessment algorithms for specific BC subtypes that are validated in ethnically 
diverse populations is a high priority. Having a user friendly interface that enables women and 
clinicians to identify and manage risk will be important in implementing risk management. 
Implementation researchers and policy-makers should consider how models can be applied to 
populations in order to ensure that women at increased risk are identified at an early age while there is 
still time to effectively reduce their risk with existing proven interventions. To efficiently deliver this 
we will need to define which treatments can be given at which ages for maximal protection. Pre-
clinical studies will be informative in determining such dosing regimens. The treatments will also 
need to be well tolerated as they are being used in otherwise healthy individuals. Ultimately it is 
hoped that risk assessment models  might one day predict not only whether a woman will or will not 
develop BC but at what age, so that risk-reducing interventions can be applied in the most appropriate 
timeframe. The perfect intervention may target all molecular subtypes of BC, but given their different 
etiologies, this is unlikely, so models that predict subtype and thus enable the application of future 
medications that target particular subtypes would be optimal.  
As we move to find preventative therapies that do not rely on disrupting estrogen activity, we need to 
understand more about what drives increased BC risk. Assessing the pre-neoplastic breast tissue of 
women at increased risk of basal-like BC (BRCA1 mutation carriers) led to the identification of the 
cell of origin and the first cell-specific potential BC preventative (Figure 3).  Now we need to ask how 
BRCA2 mutation status alters the breast epithelial hierarchy and if this can be targeted for 
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preventative therapies. Furthermore, how do BMI, age and reproductive factors alter breast epithelial 
cells. If we find that aberrant control of distinct populations of breast epithelial cells are responsible 
for the generation of the different BC subtypes (such as for RANK
+
 luminal progenitors and basal-like 
BC), the development of new preventives may need to be subtype specific.  
 
In the 20th century, the eradication or control of many deadly communicable diseases transformed 
human health 261. It is not impossible to imagine that, with the augmentation of our existing BC 
prevention toolbox with future discoveries, we could achieve the same for BC in the 21
st
 century. By 
focusing on the risk factors for BC and their incorporation into effective risk estimation tools we will 
identify those women at increased risk. Research into the mechanisms underlying risks will be 
instrumental in driving the development of therapies to effectively counter or manage those risks and 
prevent BC where we can. It is unlikely we can reverse the reproductive choices that are driving 
hormonally responsive BC; however, public health awareness and preventative therapies will be 
important, as will a focus on the development of improved hormonal therapies (MHT and OCP) that 
deliver symptom control and contraceptive benefits, but without increasing BC risk. Whilst this may 















Table 1: Comparison of model inputs for major breast cancer risk estimation models 
 
Model input 





















Individual factors   
Age ≥35 ✓ ✓ ✓ ✓ 
Race or 
ethnicity  
✓ ✓ ✓ ✓ ✓ 
Age at 
menarche 
 ✓    ✓    NA  NA  NA 
Age at 
menopause 
 NA  ✓    NA  NA  NA 
Age at 1
st
 birth  ✓    ✓    NA  NA  NA 
Parity  NA  ✓    NA  NA  NA 




 NA  NA  NA  NA  NA 
MHT use  NA  ✓    NA  NA  NA 
Alcohol use  NA  NA  NA  NA  NA 
Breast-related factors   
No. of prior 
breast biopsies  
 ✓    ✓    NA  ✓    NA 
Atypical 
hyperplasia 
✓ ✓  NA  NA  NA 
LCIS  NA ✓  NA  NA  NA 
Other benign 
pathology 
 NA ✓  NA  NA  NA 
Mammographi
c density  
 NA ✓  NA ✓  NA 
Therapeutic 
irradiation*  




 NA ✓ ✓  NA ✓ 
Other high risk 
genes 




 NA ✓  NA  NA * 
FHx factors*** 
Cancer status 
of 1st degree 
relatives   






 NA ✓ ✓  NA ✓** 
Age at BC 
diagnosis  
 NA ✓ ✓  NA ✓ 
Pathology of 
BC 
 NA  NA ✓  NA ✓ 
Bilateral BC  NA ✓ ✓  NA ✓ 
Male BC  NA ✓ ✓  NA ✓ 
Ovarian cancer  NA ✓ ✓  NA ✓ 
Pancreatic and 
prostate cancer 
 NA  NA  NA  NA ✓ 
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BC, breast cancer; BCRAT, breast cancer risk assessment tool; BCSC, breast cancer 
surveillance consortium; BMI, body mass index; BOADICEA, breast and ovarian analysis of 
disease incidence and carrier estimation algorithm; FHx, family history; MHT, menopausal 
hormone therapy; NA, not applicable; LCIS, lobular carcinoma in situ; SNPs, single 
nucleotide polymorphisms  
* eg mantle radiation for Hodgkins disease 
**newest version of BOADICEA, V5, includes SNPs.  
***includes family history of breast, ovarian, pancreatic and prostate cancer in 1st, 2nd and 
3rd degree relatives 
 
 
Table 2: UK and US breast cancer prevention guidelines for women at increased risk  




























 BRCA1 – 
between 
35-40yrs 











  ≥35 years 
old with 5 
year BC risk 
>1.7% 









 MHT (consider associated 
BC risk)  
 Alcohol (limit consumption) 
 Exercise (premenopausal: 
vigorous; postmenopausal: 










risk ≥ 30% 
Consider for: 
 lifetime 
risk ≥ 30% 
 offer MHT 
up until 
Consider if: 




 OCP- (if >35 years old 
inform of increased risk of 
BC. For BRCA1 mutation 
carriers discuss potential 
increased risk of BC before 
Genetic testing  NA ✓ ✓  NA ✓ 
Mastectomy 
status 
 NA  NA ✓  NA  NA 
Oophorectomy 
status 























if the individual 










 MHT (advise of increased 
BC risk; tailor use to 
individual circumstances; 
use lowest dose for shortest 
time possible (generally not 




 Alcohol (advise of 
increased BC risk) 
 Smoking (advise cessation) 




NA NA Consider if: 
 ≥35 years old 
with 5 year risk 










ACSO, American society of clinical oncology; BC, breast cancer; FHx, family history; HRT, 
hormone replacement therapy; LCIS, lobular carcinoma in situ; MHT, menopausal hormone 
therapy; NA, not applicable; NCCN, (US) national comprehensive cancer network; NICE, 
(UK) national institute for health and care excellence; OC, ovarian cancer; OCP, oral 
contraceptive pill; RRBM, risk-reducing bilateral mastectomy; RRSO, risk-reducing bilateral 
salpingo-oophorectomy; RT, radiotherapy.  
# 5 year course; no guideline currently recommends a 3 year lower dose course as tested in 
DeCensi 2019 
228
, although ASCO guidelines suggest women who stop tamoxifen after 3 
years will likely still derive benefit and that for women with intraepithelial neoplasia the 
low 5mg per day dose of tamoxifen may be an alternative if there are concerns over 
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ABCSG = Austrian Breast & Colorectal Cancer Study Group; ADH, atypical ductal hyperplasia; ALDH1, aldehyde 
dehydrogenase 1; AE, adverse events; ALH, atypical lobular hyperplasia; BC, breast cancer; BCRAT, breast 
cancer risk assessment tool; BIRADS, breast imaging reporting and data system; CVD, cardiovascular disease; 
DCIS, ductal carcinoma in situ; ER, estrogen receptor; FHx, family history; LCIS, lobular carcinoma in situ; MRI, 
magnetic resonance imaging; NCI, national cancer institute; N/A, not applicable; PR, progesterone receptor; 
QOL, quality of life; RANK, receptor activator of nuclear factor-κB; RANKL, RANK ligand; s/c, subcutaneous; 




Figure 1:| Breast cancer risk modifiers and population frequency. The population frequency 
(horizontal x-axis) of genetic and non-genetic breast cancer risk modifiers are shown with their effects 
on, or associations with, relative risk of breast cancer (vertical y-axis). Rare, high risk alleles are 
shown as are rare, moderate risk alleles considered to have sufficient evidence to support their 
association. Examples of common low penetrance variants, of which there are now several hundred, 
are also listed
18,19,21-23
. For menopausal hormone therapy (MHT) and oral contraceptive pill (OCP) 
use, combined estrogen and progestogen therapy is assumed and dark blue denotes risk for current, 
long term users, mid blue denotes shorter periods of use and light blue past users
33,267,268
. * refers only 
to postmenopausal obesity
269
. # refers to 2 glasses of alcohol per day, which is the average 
consumption level in the 72% of the high socio-demographic index population who are drinkers
134,144
. 
Exercise refers to most active compared to least physically active
124
. The relative risk reduction 
associated with breastfeeding is for 12 months of cumulative breastfeeding
31
. Parity refers to a first 
full term childbirth prior to 25 years of age
35
. The RR of breast cancer in women with moderate to 
high mammographic density (>25% to >75% density) is 1.8 to 6.0 compared to women with low 
mammographic density
104
. Currently 50% of the female population are considered to have moderate 
(25-50%) to high (>75%) breast density 107. Yellow refers to genetic risk factors, blue to reproductive 
and orange to lifestyle. APOBEC3, apolipoprotein B mRNA editing enzyme catalytic polypeptide-
like; ATM, ataxia telangiectasia mutated; cadherin-1 (CDH1; which encodes E-cadherin), CASP8, 
caspase 8; CHEK2, checkpoint kinase 2; FGFR2, fibroblast growth factor receptor 2; NBN, nibrin; 




Figure 2The biological differences between high and low mammographic density.  
Breast tissue with high mammographic density (HMD) has been shown to have increased levels of 
stroma and epithelium compared with areas with low mammographic density (LMD)
108
. Note that 
within the epithelium however, an increase in stem or progenitor cells has not yet been shown. Tissue 
with HMD also has an increased amount of structured collagen. BCs are often localized in areas of 
dense collagen or are stimulated to grow when the breast has increased stromal collagen
270
. 
Additionally, the collagen-binding proteoglycans, lumican, decorin, fibromodulin, and biglycan are 
also associated with HMD
271
. Lumican can induce initiation and progression of BC by increasing 
angiogenesis, epithelial cell growth, migration, and invasion
272
. The increased stiffness resulting from 
these extracellular matrix (ECM) changes may drive cancer formation through higher mechanical 
force and resistance to contractility on the epithelial cells (via focal adhesions and the RHO GTPase 
signalling pathway) driving proliferation 273. Stromal fibroblasts in areas of HMD have also been 
shown to exhibit gene expression signatures associated with cancer stimulating pathways such as 
stress response, inflammation, stemness, and signal transduction
274
. BCs with immune infiltration are 
known to have better prognosis and may respond to chemotherapeutics and be responsive to immune 
based therapies 
275,276
. However, less is known about immune infiltration in the normal breast and 
early, pre-invasive lesions. Tissue with HMD has been shown to have a pro-tumorigenic immune 
microenvironment including increased innate (macrophages and dendritic cells), adaptive (T and B 
cells) and increased interleukin 6 (IL-6), which may aid escape from immune regulation for early 
tumor cell variants
109
. Furthermore, the ECM has been shown to modulate activation, fate 
determination, and chemotaxis of immune cells
277-279
 indicating that the changes may be interrelated.  
 
Figure 3: Developing novel preventatives based on a deeper understanding of the early events in 
breast cancer development. Schematic of the normal breast, pre-neoplastic changes and invasive 
breast cancer (BC) showing the alterations that occur and the drugs currently used in prevention and 
treatment. One of the earliest stages of cancer development is the transformation of a single cell 
within the epithelial layer. In the normal breast, the oncogene expressing cells are ejected from the 
epithelium by surrounding normal cells in a process called oncogenic extrusion 
280
. Work is 
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undergoing to assess oncogenic extrusion in early tumour development and the factors that control it. 
The selective estrogen receptor modulator (SERM), tamoxifen is used to prevent BC in women with 
normal breast tissue and also in those women at high risk of BC owing to pathogenic mutations. 
Recently, denosumab, a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor has shown 
promising results in BC prevention in BRCA1 mutation carriers by targeting the RANK
+
 luminal 
progenitor population that is increased in these women. Future work should determine whether 
BRCA2 mutation status also alters the breast epithelial hierarchy and how this can be exploited to 
develop therapies for BRCA2 mutation carriers. In terms of the non-genetic risk factors it is important 
that we define how body mass index (BMI), age and reproductive factors alter the breast epithelial 
cells. The epithelial cells sit embedded in a stromal and immune microenvironment, which is 
emerging as having a significant role in the growth and progression of pre-invasive and invasive BC 
258,260
. In the stroma of pre-neoplastic lesions fibroblasts become activated and the macrophage and T 
cell populations are altered. Currently immune modulating therapies are not used this early in tumour 
development but as we define how the immune system changes at this time, it is possible they can 
also be used to prevent or delay tumour formation. In invasive BC, the luminal epithelial cells have 
transformed, extrusion does not occur and the basement membrane is breached. The epithelial cells 
can be targeted in invasive BC with, tamoxifen (for estrogen receptor (ER)
+
BCs) and trastuzumab (for 




). There are also additional changes to the 
stromal fibroblasts and immune cells (for example, fewer T cells and repolarisation of macrophages), 
which can further stimulate cancer growth. Immune-based therapies, such as pembrolizumab, the 
programmed cell death protein 1 (PD1) inhibitor, inhibitors of granulocyte colony-stimulating factor 
receptor (GCSFR) and colony stimulating factor 1 receptor  (CSF1R) are currently being explored in 
cancer treatment. Similarly, cancer associated fibroblast (CAF)-targeting therapies, such as fibroblast 
activation protein (FAP) antibodies conjugated to cytotoxic drugs (FAP5–DM1) are being 
investigated. As we begin to understand more about the changes occurring in the pre-neoplastic 
breast, it can be envisioned that the use of additional epithelial and stromal or immune-targeted 




 The role of exogenous hormones in breast cancer risk  
A major change in reproductive behaviours in the last century has been the introduction and 
widespread use of exogenous estrogens in the form of hormonal contraceptives and menopausal 
hormone therapy (MHT), 
33,267,281-283
 which increase ER positive breast cancer (BC) risk
33,268,282-284
. 
The oral contraceptive pill (OCP) is now the most popular form of contraception with a quarter of 




In the late 1990s, a meta-analysis of individual data from over 150,000 women demonstrated that 
current users of OCPs had a 24% increased relative risk (RR) of BC. The increased risk attenuates 
after cessation and is no longer evident 10 years post-cessation
267
. A more recent, large Danish study 
supports these findings and also showed an increased risk associated with use of progestogen-
containing intrauterine devices
268
. For OCPs, the RR of BC is higher in current users who commenced 
use prior to 20 years of age, but because the baseline risk of BC at such a young age is very low, for 
any given duration of use, early commencement of OCP does not contribute to more BC being 
diagnosed in younger women than in those who start later in life
267
. Duration of use also impacts on 
risk; 5 years of use is associated with at least a 5% increased RR whilst 10 and 13 years is associated 




 A key point is that the increase in absolute risk of BC associated with hormonal contraception is low 
when the underlying risk is low (e.g. in young women at average lifetime risk of the disease), but 
when the underlying risk is higher (e.g. older premenopausal women with a strong family history of 
the disease) the increase in absolute risk is likely to be of more importance. In fact, it has been 
estimated that 7% of BC burden for premenopausal women is owing to the use of hormonal 
contraceptives for 5 or more years
136
. US statistics indicate that as much as 10% of OCP users are 
older premenopausal women aged 40-49
286
. Therefore, when estimating the risk–benefit ratio for an 




The Collaborative Group on Hormonal Factors in Breast Cancer recently published their individual 
participant meta-analysis of the worldwide epidemiological evidence related to MHT and BC risk
33
. 
They estimated that about 1 million of the approximately 20 million BCs diagnosed in Western 
countries since 1990 were due to MHT use
33
. Every MHT type, except vaginal estrogens increased 
BC risk (compared with non-users), which steadily rose with duration of use and were greater for 
oestrogen and progestogen preparations (combined MHT) than oestrogen only ones. Specifically, for 
combined MHT use (1-4 years), there was a 60% increase in risk of BC (RR: 1·60), and for estrogen 
only MHT, a 17% increase (RR: 1·17). Risk was greater for longer durations of use: for example, for 
5-14 years of combined MHT use, the risk was more than doubled (RR: 2·08) and it was 33% higher 
for estrogen-only MHT (RR: 1·33). Furthermore, the RRs during years 5–14 were much greater for 
ER positive tumours than for ER negative tumours. After ceasing MHT, some excess risk persisted 
for more than 10 years but its magnitude was dependent on the duration of previous use 
33
. These 
findings are consistent with other large studies
284,287-289
, although the women’s health initiative (WHI) 
randomised trial showed a protective effect of estrogen only MHT for BC, resulting in ongoing 




The relationship between estrogen and BC risk is complex and it is hoped that pre-clinical work 
assessing the effects of estrogen alone and estrogen – progestogen therapies on breast tissue may 
reveal how these therapies alter the breast to impact on cancer risk.  
Glossary  
 
ADIPOKINE: cell signalling protein secreted by adipose (fat) cells  
 
Basal-like breast cancer: breast cancer subtype that is more prevalent in African-American women, 
and are characterised by high histological grade, high mitotic indices and lack of ER and PR abd 




BC RISK ESTIMATION MODELS: Tools that estimate a person’s likelihood of developing breast cancer 





BILATERAL SALPINGO-OOPHORECTOMY: A surgical procedure to remove both ovaries and fallopian 
tubes.  
 
CALIBRATION: the ratio of the observed number of breast cancer cases to the expected number; 
values of 1 indicate optimal calibration 
 
DISCRIMINATORY ACCURACY: the ability of a risk model to separate individuals who will get 
breast cancer from those who will not. A value of 1.0 represents perfect discrimination, a value of 0.5 
means that the model performance is no better than chance alone, values of 0.6-0.7 are considered 
good and 0.5-0.6 sufficient 
 
GYNAECOMASTIA: excessive enlargement of the male breast. May be unilateral (one side) or 
bilateral (both) 
 
HAZARDS RATIO (HR): a measure of how often a particular event happens in one group compared 
to another group, over time. A HR=1.0 means that there is no difference in survival between the two 
groups. A HR > 1.0 or <1.0 means that survival was better in one of the groups. 
 
 
HOMOLOGOUS RECOMBINATION: the exchange of nucleotide sequences  between two similar or 
identical molecules of DNA. It is used by cells to accurately repair damage that occurs on both strands 
of DNA, such as double-strand breaks or interstrand DNA crosslinks.  
 
KLINEFELTER SYNDROME: A genetic condition, affecting about 1 in every 550 men, in which a 





LUMINAL PROGENITORS: A type of luminal epithelial cell within the mammary epithelium that 
has both luminal differentiation markers and progenitor activity (colony forming and repopulating 
activity in vivo).   
 
MAMMARY STEM CELLS (MASCS): Cells within the mammary gland that have the capacity to form a 
new mammary tree when transplanted into a cleared mammary fat pad. Reside within the 
basal/myoepithelial compartment and can be identified with CD24/EpCAM and either CD29 or 
CD49f.  
 
Mammographic density: Mammographic density (MD) describes the extent of white or radio-opaque 
tissue (dense area) on a mammogram, and percent MD is used to represent this dense area as a 
proportion of the total tissue area of the breast on a mammogram. 
 
MENARCHE: The time in a girl’s life when her first menstrual bleeding or period begins.  
 
MENOPAUSAL HORMONE THERAPY: sex hormones given to treat symptoms or prevent long-
term morbidities associated with female menopause Also known as hormone replacement therapy 
(HRT)  
 
ODDS RATIO (OR): a statistic that quantifies the strength of the association between an exposure 
and an outcome. An OR=1 means the exposure does not affect odds of outcome, an OR>1 means the 
exposure is associated with higher odds of outcome and that an OR<1 means the exposure is 
associated with lower odds of outcome.  
 
ORAL CONTRACEPTIVE PILL: (OCP). A birth control pill taken orally. Most contain estrogen and 
progesterone which when given at certain times in the mentrual cycle at defined doses can prevent the 




PARITY: The state of having borne offspring (liveborn or stillborn). Also used to indicate the number 
of pregnancies reaching viable gestational age (liveborn or stillborn – pregnancies resulting in 
multiple births, such as twins, count as 1)  
 
POST-PARTUM INVOLUTION PROCESS: A cell-death–mediated process by which the lactating 
breast returns to the pre-pregnant state after weaning (or after childbirth if lactation is not initiated). It 
is characterized by robust tissue remodeling. 
 
RELATIVE RISK (RR): a ratio of the probability of an event occurring in the group exposed to the 
modifier of interest versus the probability of the event occurring in the non-exposed group. A relative 
risk of 1.5 means people exposed to the risk modifier, on average have a 50% higher risk than those 
not exposed. 
 
ABSOLUTE RISK: The absolute risk of a disease is the risk of developing the disease over a time period, e.g. a 
person may have a 1 in 10 risk (i.e a 10% risk) of a certain disease in their life. Absolute risk is one of the most 
understandable ways of communicating health risks to the general public. 
 
BILATERAL MASTECTOMY: removal of as much breast tissue as possible to reduce breast cancer risk  
 
TRANSDERMAL THERAPY: a route of drug administration wherein the drug is delivered across the skin, 
via patches or creams, for systemic distribution. 
 
Polygenic disease: A genetic disorder that is caused by the combined action of more than one gene 
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Table of contents summary 
This review presents the evidence for the role of risk factors in breast cancer incidence and their 
inclusion in risk estimation tools as a step towards precision prevention to specifically target those 
women at increased risk for  appropriate risk-reducing interventions.  
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